Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Poland Crypto Bill Clears Sejm Again, Defying President — Will “Restrictive” Rules Stick? - 2Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
- 3My Dad Can't Travel Like He Used to, but Slowing Down Doesn't Mean Stopping
- 4Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- 5Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- Doulas play essential roles in reproductive health care – and more states are beginning to recognize it
- Haifa refinery said hit in latest Iranian missile barrage
- Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- Figure out How to Clean and Really focus on Your Lab Jewel
- Happy with Running Shoes for 2024
- New funding transforms lives by expanding electricity access across Africa
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- Renewables cover over 50% of German electricity consumption in Q1
